Intraneural IFG-1 in cryopreserved nerve isografts increase neural regeneration and functional recovery in the rat sciatic nerve by González Porto, Sara Alicia et al.
Neurosurgery. 2019;85(3):423-431 
Intraneural IFG-1 in Cryopreserved Nerve Isografts Increase 
Neural Regeneration and Functional Recovery in the Rat 
Sciatic Nerve 
Sara Alicia González Porto, MD∗ Nieves Domenech, PhD‡ § Francisco J. Blanco, 
MD, PhD¶ Alberto Centeno Cortés, VMD|| Casto Rivadulla Fernández, PhD# 
Ángel Álvarez Jorge, MD, PhD∗∗ Jacinto Sánchez Ibáñez, MD‡‡ Esther Rendal 
Vázquez, PhD‡‡ 
∗Servicio de Cirugía Plástica, Hospital POVISA, Vigo, Spain; ‡Biobanco A Coruña, Instituto de 
Investigación Biomédica de A Coruña (INIBIC), Servicio Galego de Saúde (SERGAS), A Coruña, Spain; 
§Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain; 
¶Grupo de Investigación de ProteómicaPBR2-ProteoRed/ISCIII-Servicio de Reumatología, Instituto de 
Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña 
(CHUAC), Servicio Galego de Saúde (SERGAS), Universidade da Coruña (UDC), A Coruña, Spain; ||Centro 
Tecnológico de Formación XXIAC, Instituto de Investigacións Biomédicas de A Coruña (INIBIC), Servicio 
Galego de Saúde (SERGAS), A Coruña, Spain; #Grupo de Neurociencia e Control Motor, NEUROcom, 
Facultade de Ciencias da Saúde, Departamento de Ciencias Biomédicas, Fisioterapia e Medicina, Instituto 
de Investigacións Biomédicas de A Coruña (INIBIC), A Coruña, Spain; ∗∗Servicio de Cirugía Plástica, 
Complexo Hospitalario Universitario de A Coruña (CHUAC), Servicio Galego de Saúde (SERGAS), A 
Coruña, Spain; ‡‡Unidad de Criobiología, Banco de Tejidos, Complexo Hospitalario Universitario de A 
Coruña (CHUAC), Servicio Galego de Saúde (SERGAS), A Coruña, Spain 
Abstract 
BACKGROUND: Insulin-like growth factor 1 (IGF-1) was found to stimulate Schwann cell mitosis. 
Exogenous IGF-1 may improve nerve regeneration after cryopreservation. 
OBJECTIVE: To evaulate the effect of intraneural administration of IGF-1 in cryopreserved nerve isografts. 
METHODS: Eighteen millimeter grafts were used for bridging an 18-mm defect in the rat sciatic nerve. A 
total of 57 rats were randomly divided into three groups: (1) autograft (Group 1); (2) cryopreserved isograft 
(Group 2); (3) cryopreserved isograft with intraneural IGF-1 administration (Group 3). 12 weeks after 
surgery, functional recovery (Sciatic functional index [SFI], Swing speed [SS], nerve conduction velocity 
[NCV], amplitude of compound motor action potentials [CMAP], and gastrocnemius muscle index [GMI]) 
and nerve regeneration (myelin sheath area, total fiber counts, fiber density, and fiber width) were all 
evaluated. 
RESULTS: The intraneural injection of IGF-1 significantly improved SFI and SS at weeks 10 and 12. There 
were no statistical differences between Groups 1 and 3 in any of the SFI or SS evaluations. CMAP and NCV 
in Group 1 were significantly higher than in Groups 2 and 3, and Group 3 had significantly higher CMAP and 
NCV compared to Group 2. No significant differences were found in fiber width. The number of nerve fibers, 
percentage of myelinated fibers, fiber density, and GMI was significantly higher in Group 1 compared to 
Group 2, but no significant differences were found between Groups 1 and 3. 
CONCLUSION: The results show that intraneural injection of IGF-1 in an 18 mm cryopreserved isograft 
improve axonal regeneration and functional recovery. 
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Despite the advances in microsurgery, the reconstruction of major defects in the peripheral nerve 
continues to be a challenge in clinical practice.
1,2
 The optimal treatment for a peripheral nerve 
defect is the use of nerve grafts from the patient him or herself (autograft). Disadvantages of this 
technique include limited availability and iatrogenesis in the nerve graft donor area, consisting of 
anesthesia or local pain.
3,4
 Among the alternatives to the autografts, the nerve allografts are 




Cryopreservation is a method of conservation of tissues by means of cold treatment, which allows 
metabolic needs of tissues to be reduced to a minimum. Nerve cryopreservation is used to reduce 
immunogenicity within the graft, although maintaining viable Schwann cells and the scaffold for 
which Schwann cells can travel.
6,7 
This technique also permits long-term storage of nerve tissue in 
tissue banks, and immediate availability of cryopreserved allografts. Immunosuppression is 
necessary to avoid rejection of the graft, although Squintani et al
8
 reported the use of 
cryopreserved nerve allografts in the clinical setting with no adjuvant immunosuppression.
9
 The 
aim of the cryopreservation process is to keep Schwann cells viable, so that, theoretically, nerve 




Apart from the scaffold for the regeneration of the nerve, we know that growth factors aid nerve 
regeneration.
11
 Insulin-like growth factor 1 (IGF-1) is a growth factor which has been shown to 
stimulate Schwann cell mitosis, so that it should boost the regeneration of the cryopreserved 
isograft.
12
 This growth factor improves nerve regeneration when administered locally on a daily 
basis or every other day.
13-15
 Single intraneural dosing and evaluation of the local effects of this 
neurotrophic factor are needed. 
METHODS 
Animals 
The study was approved by the Institutional Review Board and all animal care complied with the 
Guide for the Care and Use of Laboratory Animals. Fifty-seven female adult Wistar-Lewis rats, 
(11-13 wk of age, weight 210-280 g) were randomized to 1 of the following groups: autograft 
(Group 1), cryopreserved isograft (Group 2), and cryopreserved isograft and intraneural IGF-1 
(Group 3). Using the same strain of animal as donors would allow us to study the effects of 
cryopreservation over the nerve isograft, without interference of rejection. 
 
In each of the three groups, 19 animals underwent sciatic nerve surgery. Nineteen rats were used 
as nerve isograft donors. 
 
Inhalation anesthesia was applied, using sevoflurane. Surgery was performed under aseptic 
conditions using an operating microscope (Optomic OP-C12, Madrid, Spain). 
Preparation of Cryopreserved Nerve Isografts 
Nineteen rats underwent bilateral sciatic nerve surgery. Thirty-eight sciatic isografts were 
harvested. By means of a dorsal incision in both gluteal regions, biceps, and semitendinous 
muscles were exposed. After dissecting the sciatic nerve between these muscles, a 25-mm nerve 
graft was obtained and stored individually in sterile recipients in Medium 199 with 10% DMSO 
(dimethyl sulfoxide) and 4% human albumin. The cryopreservation process was performed using a 
cooling rate of 1°C per minute down to −140°C, the nerves being stored in nitrogen gas for 3 to 4 




Under inhalation anaesthesia, the rats were placed in a left lateral decubitus position. A 
longitudinal dorsal incision was made in the left gluteal area. An 18-mm length of sciatic nerve 
was removed at mid-thigh level and the nerve defect was repaired by (1) using the same autograft 
that has been resected in Group 1 (Auto), (2) using cryopreserved nerve isograft alone in Group 2 
(Iso), or (3) using cryopreserved nerve isograft and intraneural IGF-1 injection in Group 3 (Iso-
IGF1; see Figure 1, which illustrates a schematic representation of the 3 groups). All grafts were 
18 mm in length, and the repair was tension-free, using 9-0 nylon suture at each end. In Group 3, 
the intraneural injection of recombinant human IGF-1, 25 μL (10 mg/ml, Increlex
®
 2 mg) was 
performed after the distal suture was made, at epineural level of the proximal graft, in order to 
preserve the fascicular nerve architecture, using a micropipette (Stripper
®
 Tip, 135 μm, Origio, 
Denmark) through the proximal end of the graft. 
 
 
FIGURE 1. Schematic representation of the groups designed in this study. In Group 1, the gap of the sciatic 
nerve was bridged with an autograft from the same rat. In Group 2, cryopreserved isografts were used to 
reconstruct the sciatic nerve defect. In Group 3, IGF-1 was injected into the cryopreserved isografts used to 
reconstruct the defect. 
  
Animals were monitored postoperatively for infection, pain, and distress. After the functional and 
histological assessment at 12 wk, rats were euthanized with intrapericardial injections of 
Potassium Chloride (2 mEq/ml, B. Braun, Aschaffenburg, Germany). 
Sciatic Functional Index and Swing Speed 
Sciatic functional index (SFI) and swing speed (SS) were taken before surgery (0 wk) and after 2, 
4, 6, 8, 10, and 12 wk postoperatively, according to the method described by Westerga and 
Gramsbergen
17
 and the formula proposed by Chen et al,
18
 respectively. The video recording 
technique was performed as reported by Walker et al
19
 and Dijkstra et al.
20 
 
The variables measured for the feet on the experimental (E) and normal side (N; expressed in 
milimeters) were as follows: 
 
1. Print length (PL): Distance between heel and toe. 
2. Toe spread (TS): Distance between first and fifth toes. 
3. Intermediary toe spread (IT): Distance between second and fourth toes. 
 
SFI was calculated according to the method described by De Medinacelli,
21
 using the modified 





SFI = −38.3 (
𝐸𝑃𝐿 − 𝑁𝑃𝐿
𝑁𝑃𝐿
) + 109.5 (
𝐸𝑇𝑆 − 𝑁𝑇𝑆
𝑁𝑇𝑆
) + 13.3 (
𝐸𝐼𝑇 − 𝑁𝐼𝑇
𝑁𝐼𝑇
) − 8.8 
 
 
In general terms, SFI values vary from 0 (normal nerve function) to −100 (absence of sciatic 
function). 
 
SS is the speed at which limbs travel between steps, and it was calculated with a manually 
quantitative gait analysis method, dividing the distance of the step by the time of the swing phase. 
The relative SS was calculated as reported by Chen et al
18
 as the ratio of the SS of the left 
hindlimb (experimental side, LSS) to the SS of the right hindlimb (normal side, RSS), and 
standarized against the baseline ratio (ratio of baseline SS of the left hindlimb, bLSS; to baseline 











The theoretical values for relative SS vary from 0% (absence of sciatic function) to 100% (normal 
nerve function), being usually above 30% after sciatic nerve injury. 
Neural Electrophysiology 
The electrophysiological recording was determined as reported previously.
23
 Twelve weeks 
following surgery, the electrophysiology study was performed using an amplifier (AM Systems, 
Jaen, Spain) connected to a Power 1401 interface (Cambridge Electronic Design Limited, 
Cambridge, United Kingdom), to measure the compound motor action potential (CMAP) and 
CMAP onset latencies. The registers were stored and processed using Spike 2 software (Centre 
d’Estudis Demogràfics, Barcelona, Spain), by an electrophysiologist, blinded to the method of 
treatment. Under inhalation anesthesia, surgical exposure of the grafted sciatic nerve was realized. 
Stimulating bipolar electrodes were placed both proximal and distal to the graft, and the register 
electrode was placed in the gastrocnemius muscle. The distance between the bipolar electrodes 
was recorded. The difference of latencies between both registers was used to calculate the motor 
nerve conduction velocity (MNCV). 
 




𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑡𝑤𝑜 𝑝𝑜𝑖𝑛𝑡𝑠 (𝑚)




Gastrocnemius Mass Index 
After electrophysiology studies and histology nerve sampling were completed, gastrocnemius 
muscles from both the normal (right) and experimental (left) side were removed and weighted 
using an electronic balance with a precision of 1/10 000 g. 
 




𝑊𝑒𝑡 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝑠𝑖𝑑𝑒 (𝑙𝑒𝑓𝑡)





After the electrophysiological studies were completed, 3-mm samples were taken proximal to the 
distal suture line for histological analysis. Fixation with 10% formalin was performed for 24 h, 
followed by gradient alcohol dehydration and paraffin inclusion. Cross-sections 4 μm in width 
were cut with a microtome. Deparaffinization of the slices was performed at 60°C with xylene. 
They were later hydrated by immersion in 100° alcohol, 96° alcohol and tap water, stained by 
Harris hematoxylin for 5 min, rinsed in tap water, incubated in eosin staining for 1 min, 
dehydrated in 96° alcohol and 100° alcohol and immersed in xylene. Eight hematoxylin and eosin 
stained slices per nerve were observed under light microscopy in order to observe inflammatory 
infiltrate and the general structure of the nerve. The presence and extension of perineural scar and 
hypervascularized tissue surrounding the graft were assessed by 2 blinded pathologists, through a 
semiquantitative scale. 
Electronic Microscopy 
Three-mm segments were harvested from both the distal graft and distal nerve, and fixed in 2.5% 
glutaraldehyde for 12 h at 4°C in 0.1 M cacodylate buffer with pH 7.4, followed by postfixation in 
1% osmium tetroxide, gradient acetone dehydration, and inclusion in a SPURR low-viscosity 
epoxy resin. The segments were cut with the ultramicrotome in 60 nm slices, dyed with Toluidine 
Blue, and observed under a JEM 1010 transmission electron microscope (Jeol, Akishima, Japan). 
Images were taken with a Mega View III digital camera and analyzed by analysis software (Soft 
Imaging System GmbH, Olympus, Shinjuku, Japan). The thickness of the myelin sheath, the area 
of nerve fibers, the total number of nerve fibers, the percentage of myelinated nerve fibers, and the 
density of nerve fibers were all quantified in 10 random fields of vision, magnified 2000 times, in 
slices from the distal nerve fragment. The pathology technician was blinded to the method of 
treatment. 
Statistical Analysis 
A descriptive analysis was performed for all the variables included, expressing them as the 
mean ± SD (Standard Deviation), in addition to the 95% confidence interval. Statistical analysis 
was carried out with the nonparametric Kruskal–Wallis test. The Mann–Whitney U test was then 
used as a post hoc test. The correlations between the quantitative measurements were determined 
by means of the Spearman correlation coefficient. SPSS 22.0 software (IBM Inc, Armonk, New 
York) was used for analysis. P < .05 (<5%) was considered a significant difference. 
RESULTS 
Sciatic Functional Index and Swing Speed 
During week 2, significant differences were found between the groups in SFI (P = .04), but not in 
SS (P = .15; see Figure 2 showing a schematic representation of SS). Group 2 SFI was 
significantly lower than that of Group 1 (P = .04) and Group 3 (P = .01), no differences being 
found between Groups 1 and 3 (P = .66). At 2 wk there is not enough time for reinnervation in a 
18-mm graft, and the absence of significant differences in SS is more reliable than the results of 





FIGURE 2. Graph showing the evolution of SS in the 3 groups. *P < .05 compared to the autograft. There 
were no significant differences between groups until week 10. This could be explained because ten weeks is 
roughly the time frame expected for the regeneration front to reach the distal target. SS was superior in Group 
1 compared with Groups 2 and 3 both in weeks 10 and 12. However, there are significant differences between 
Group 1 and Group 2 but not between Group 1 and Group 3. Group 3 significantly improved SS results in 
weeks 10 and 12 compared with Group 2. 
In the SFI of weeks 4, 6, and 8, no statistically significant differences were found 
(P = .13, P = .06, and P = .08 respectively), nor in the SS of weeks 4, 6, and 8 (P = .21, P = .23, 
and P = .11 respectively). 
 
During weeks 10 and 12, statistically significant differences were found between the groups in the 
SFI (P = .04 and P = .01, respectively) and in the SS (P < .001 in both weeks). SFI was 
significantly greater in Group 1 compared with Group 2 (P = .01 in week 10, P = .001 in week 12), 
with no difference being found between Groups 1 and 3 (P = .32 in week 10, P = .11 in week 12), 
nor between Groups 2 and 3 (P = .21 in week 10, P = .06 in week 12). SS was also superior in 
Group 1 compared with Group 2 (P < .001 in both weeks 10 and 12), without significant 
difference between Groups 1 and 3 (P = .12 in week 10, P = .079 in week 12). SS in Group 3 was 
significantly greater compared with Group 2 (P = .001 in week 10, P < .001 in week 12). 
  
Neural Electrophysiology 
Statistically significant differences were found between the groups in CMAP (P = .001) and nerve 
conduction velocity (NCV) (P = .001), which were significantly higher in Group 1 than in Group 2 
(P = .001 in CMAP, P = .001 in NVC) and Group 3 (P = .005 in CMAP, P = .02 in NVC), and 
higher in Group 3 compared with Group 2 (P = .04 in CMAP, P = .04 in NVC). 
Gastrocnemius Mass Index 
Statistically significant differences were found between the 3 groups in GMI (P = .001), 
significantly lower in Group 2 compared with Groups 1 and 3 (P = .001 between Groups 1 and 2, 
and P = .001 between Groups 2 and 3), no significant differences being found between Groups 1 
and 3 (P = .42). 
Hematoxylin and Eosin 
Preservation of epineurium and perineurium was observed in all groups, as was the presence of 
neovessels. Unlike the nerve's appearance at the time of the surgical intervention, (see Figure 3, 
which illustrates the macroscopic nerve appearance after the neurorraphy), at 12 wk, epineural-
mesoneural adhesions were observed macroscopically, being observed consistently in Group 2 of 





FIGURE 3. Macroscopic view of the nerve grafts. A, View of sciatic nerve at time of neurorrhaphy of 
graft. B, View of the cryopreserved nerve isograft 12 wk after surgery. Note the scarred aspect of the nerve, 
attached to the underlying muscle bed. C, View of cryopreserved nerve isograft with IGF-1 12 wk after 
surgery, surrounded by the shiny loose epineural tissue (4×), and D, shows a detail of the epineural tissue 
(marked with a black asterisk; 40×). 
  
However, in the cryopreserved isografts from Group 3, which had been injected with intraneural 
IGF-1, the isograft was found to be surrounded by shiny hypervascularized tissue, unattached to 
the surrounding muscle, permitting blunt dissection of the isograft. By using hematoxylin and 
eosin, it was found that this tissue was made up of subcutaneous fat, rich in numerous neovessels 
(see Figure 4 for further details), quite similar to the normal epineural-mesoneural tissue. The 
presence of perineural scarring was significantly superior in Group 2 than Group 1 (P = .001) and 
3 (P = .001), and in Group 1 than Group 3 (P = .021; see Table 1 for further details). 
Hypervascularized tissue was significantly more frequent in Group 3 than Group 1 (P < .001) or 
Group 2 (P < .001), and in Group 1 than Group 2 (P = .013; see Table 2 for further detail). An 
inverse correlation between the presence of perineural scarring and hypervascularized tissue was 




FIGURE 4. Hematoxylin and eosin. 10×. A, Microscopic view of epineural scar (marked with a black 
asterisk) in a cross section of the cryopreserved isograft from Group 2. B, Microscopic view of epineural 
tissue surrounding the cryopreserved isograft with growth factor, consisting of mature adipose cells and blood 
vessels. C, Microscopic view of cross-section of normal sciatic nerve. Note the similarity of normal 
mesoneural tissue (C, marked with a black asterisk) with the loose tissue reproduced around the 
cryopreserved isograft in the group with growth factor (B). 
TABLE 1. Perineural Scarring  
 Perineural scarring 
 
0 + ++ +++ 
Autograft (Group 1)  47.4% (9/19) 47.4% (9/19) 5.2% (1/19) 0% (0/19) 
Isograft (Group 2)  5.2% (1/19) 21.1% (4/19) 42.1% (8/19) 31.5% (6/19) 
Isograft + IGF-1 (Group 3)  84.2% (16/19) 15.8% (3/19) 0% (0/19) 0% (0/19) 
Total  45.6% (26/57) 28.1 (16/57) 15.8% (9/57) 10.5% (6/57) 
 
 
Distribution of the rats of each group depending on the grade of perineural scarring showed in the histological 
analysis (0: no perineural scarring; +: mild perineural scarring; ++: moderate perineural scarring; +++: severe 
perineural scarring). 
 
The percentage of rats is shown in each cell, while the number of rats in absolute figures is shown between 
brackets. 
 
The table shows more intensity of the perineural scarring in Group 2, which was significantly superior than 
the scarring in Group 1 (P = .001) or 3 (P = .001). Group 1 had slightly more perineural scarring than Group 
3 (P = .021). 
TABLE 2. Perineural Hypervascularized Tissue 
 
 Perineural hypervascularized tissue 
 
0 + ++ +++ 
Autograft (Group 1)  52.6% (10/19) 36.8% (7/19) 5.3% (1/19) 5.3% (1/19) 
Isograft (Group 2)  94.7% (18/19) 5.3% (1/19) 0% (0/19) 0% (0/19) 
Isograft + IGF-1 (Group 3)  15.8% (3/19) 10.5% (2/19) 26.3% (5/19) 47.4% (9/19) 
Total  54.4% (31/57) 17.6% (10/57) 10.5% (6/57) 17.5% (10/57) 
 
 
Distribution of the rats of each group depending on the grade of perineural hypervascularized tissue showed 
in the histological analysis (0: no perineural hypervascularized tissue; +: mild perineural hypervascularized 
tissue; ++: moderate perineural hypervascularized tissue; +++: extensive perineural hypervascularized tissue). 
The percentage of rats is shown in each cell, while the number of rats in absolute figures is shown between 
brackets. 
 
The table reveals that the perineural hypervascularized tissue was more frequent and profuse in Group 3. The 
presence of hypervascularized tissue was significantly superior in Group 3 than Group 1 (P < .001) or Group 
2 (P < .001). Group 1 had significantly more hypervascularized tissue than Group 2 surrounding the nerve 
grafts (P = .013).
Electron Microscopy 
At 12 wk, Groups 1 and 3 had a larger number of myelinated nerve fibers than Group 2 (see 




FIGURE 5. Transmission electron microscopy. Cross section of the nerve grafts (2500×). A, Corresponds to a 
cross section of the autograft (Group 1) in its distal portion, showing good remyelinization, limited myelin 
debris, a large number of axons and similar width in nerve fibers. B, Corresponds to a cross section of the 
cryopreserved isograft (Group 2) in its distal portion. Note the irregular remyelinization, a large amount of 
myelin debris and great variation in the width of the regenerated nerve fibers. C, Corresponds to a cross 
section of the cryopreserved isograft with intraneural IGF-1 (Group 3) in its distal portion. The grafts with 
intraneural growth factor revealed more regular remyelinization, less myelin debris, and more uniform width 
in the myelin sheath and regenerated nerve fibers than those in the grafts from Group 2. 
Differences were observed between the 3 groups regarding the thickness of the myelin sheath 
(P = .001), which was significantly greater in Group 1 compared with Groups 2 (P = .001) and 3 
(P = .002), no significant differences being observed between Groups 2 and 3 (P = .15). 
 
No differences were found in the average area of nerve fibers (P = .93). 
  
The number of regenerated nerve fibers and the percentage of myelinated nerve fibers in the distal 
nerve differed significantly between the groups (P = .02 and P = .04, respectively). In both cases, 
they were significantly higher in Group 1 compared with Group 2 (P = .006 and P = .01, 
respectively), but no statistically significant differences were observed either between Groups 1 
and 3 (P = .27 in total number of nerve fibers and P = .16 in percentage of myelinated nerve 
fibers), or between Groups 2 and 3 (P = .08 in total number of nerve fibers and P = .24 in 
percentage of myelinated nerve fibers). 
 
Statistically significant differences also existed between the groups in the density of nerve fibers 
(P = .009), which was significantly higher in Group 1 compared with Group 2 (P = .002), and in 
Group 3 compared with Group 2 (P = .02), without there being any difference between Groups 1 
and 3 (P = .41). 
DISCUSSION 
In our experimental study, we observed that the intraneural injection of IGF-1 in the cryopreserved 
nerve isograft improved nerve regeneration and functional recovery, allowing similar results to 
those seen in the autograft group. Besides, in the group in which the growth factor was used, 
adipose tissue was observed around the nerve, which seems to prevent nerve scar adhesions to the 
surrounding muscle and reproduces the mesoneural tissue that surrounds the healthy nerve. 
Functional recovery parameters, such as SFI, SS, electrophysiology, and GMI, indicate 
significantly better results in the autograft when compared to the cryopreserved isograft. The 
addition of the growth factor means that outcomes improve, with the result that the cryopreserved 
isograft has functional recovery parameters similar to those of the autograft. In the 
histomorphometry, the density of nerve fibers was significantly superior when the growth factor 
was added. The improvement in the thickness of the myelin sheath, number of regenerated nerve 
fibers, and percentage of myelinated nerve fibers in the isograft with growth factor, although not 
statistically significant, demonstrates an enhanced nerve regeneration, similar to that of autograft. 
As for nerve cryopreservation, there have been few experimental studies. The nerve 
cryopreservation has to be taken into account when the results obtained in our study are observed, 
since it constitutes the reason why Group 2 has worse results than Group 1 in regeneration and 
functional recovery. This is due to the fact that cryopreservation means eliminating the viablity of 
25% to 40% of Schwann cells, and even though the graft scaffold and most of the cell population 





The protocol used in this study showed 74.9% of Schwann cell viability after cryopreservation, 





As for the cryoprotectants used in nerve cryopreservation, Zalewski et al
9 
established that the 
mixture of DMSO and formamide is superior to glycerol as a cryoprotectant for Schwann cells. 
Our group used DMSO and albumin in nerve cryopreservation, after greater viability was found 
when this protein was added to stabilize the membrane compared with using just DMSO. As for 
cooling and thawing rates, slow cooling and rapid thawing were used, as it has been shown that 




The novel factor in this study was to introduce the use of IGF-1 in a single dose, administered at 
epineural level in the cryopreserved isograft. 
 
IGF-1 presents a highly conserved structure among vertebrates, allowing the rat model to be 




Neovessel formation is essential so that axonal regeneration can take place, and IGF-1 stimulates 
neoangiogenesis in nerve regeneration,
26,27
 in addition to inducing the differentiation of non-
adipocyte precursors to fat-filled mature adipocytes.
28
 Along these lines and on the basis of the 
results of our study, we propose that the perineural adipose tissue observed in Group 3 could be 
related to the capacity of adipogenesis and neoangiogenesis of IGF-1. Further studies are 
necessary in order to find which precursors these adipocytes proceed from (satellite cells of muscle 
fibers, epineural or perineural cells), and which molecular mechanisms determine adipogenesis. 
 
As for the perineural absence of adhesions which we found in Group 3, as far as we know, no 
publication has demonstrated this effect. As opposed to what we observed in the nerve scenario, 
IGF-1 has been related to the scarring of wounds, boosting neoangiogenesis, and local recruitment 
of macrophages.
29,30
 In fact, the inhibition generated by glucocorticoids on the healing of wounds 




In order to find whether IGF-1 influences collagen formation locally, further studies would be 
necessary, with the aim of assessing the role of locally administered IGF-1 in perineural adhesions, 
an application which would be very interesting in relation to its use in clinical practice. We are 
unaware whether its local role varies according to the dose, nor the time its effect lasts. 
 
Experimental evidence exists that IGF-1 stimulates peripheral nerve 
regeneration,
11,32,33
 encouraging both growth in nerve length and nerve branching,
33–35
 and also has 





IGF-1 has been studied in different models of lesions and nerve repair in rats. Mohammadi 
et al
43
 found improved nerve regeneration when 10 μL of IGF-1 (100 ng/kg) was injected through 
an artery graft. Emel et a
44
 found increased axonal regeneration when local repeated doses of 15 
μg of IGF-1 were released over crushed sciatic nerve injuries in rats. In our study, the single dose 
administered when surgery was performed was of 25 μL (0.25 mg). In point of fact, one of the 
current limitations regarding IGF-1 is the absence of studies which examine the dose dependency 
of its effects. The maximum dose established for humans has been set at 0.012 mg/kg administered 
subcutaneously every 12 h, being only labeled to treat growth retardance due to deficits of IGF-1. 
In the current piece of work, a single dose was enough to boost nerve regeneration and functional 
recovery. We can only postulate that continuous administration by means of percutaneous pumps 
could improve results. However, when it comes to clinical practice, research into the role of single 
intraneural administration is appealing as it is much more feasible in daily practice. 
 
In our study, we decided to sacrifice all the rats at 12 wk, in order to avoid an increase in 
subgroups and the possible alpha error which could be made. The “blow-through” effect described 
by Brenner et al
45
 might determine that 4 or 8 wk after the surgical intervention there were greater 
differences between the groups. Nevertheless, we consider that the existence of significant 
differences at 12 wk is no justification for the sacrifice of more rats in order to study nerve 
regeneration 4 or 8 wk postsurgery. 
 
The rats used in our protocol had the same haplotype, so the nerve isografts did not generate 
immune rejection and in our model it was unnecessary to use immunosuppression.
46
 This model's 
design was conceived exclusively to study the role of nerve cryopreservation and the addition of 
IGF-1 in isolation, the results being unaltered by any contribution from the immune system. 
 
Lastly, we believe that the potential clinical applicability of IGF-1 in peripheral nerve lesions in 
humans needs to be grounded in fresh experimental studies which would explore its neoangiogenic 
and anti-scarring properties, and which could provide us with another tool with which to undertake 
reconstructive peripheral nerve surgery. 
  
CONCLUSION 
This experimental study has shown that the application of a single dose of IGF-1 epineurally at the 
proximal end of the cryopreserved isograft improved functional recovery and sciatic nerve 
regeneration in the Wistar–Lewis rat model. Besides, the growth factor significantly increased 
epineural adipogenesis and prevented scar adhesions in the surgical bed. 
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